Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer

MT Newswires Live11-21

Zymeworks (ZYME) and Jazz Pharmaceuticals (JAZZ) said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.

The regulator's approval was based on the HERIZON-BTC-01 trial of Ziihera, which evaluated zanidatamab as a single agent in previously treated HER2-positive biliary tract cancer, the companies added. The trial attained its primary endpoint of a confirmed objective response rate.

The partners are currently carrying out the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab with standard-of-care therapy against standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.

Zymeworks struck a deal with Jazz's Ireland unit in late 2022 to develop and commercialize zanidatamab throughout all indications in the US, Europe, Japan, and all other regions except for those Asia Pacific territories previously licensed by Zymeworks, the companies said.

Shares of Zymeworks were up 4.5% in recent Thursday premarket activity, while Jazz's stock rose 4.4%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485467661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485467661","market":"fut","top_or_hot":-1,"title":"Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer","media":"MT Newswires Live","content":"<html><body><p> Zymeworks (ZYME) and Jazz Pharmaceuticals (JAZZ) said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.</p><p>The regulator's approval was based on the HERIZON-BTC-01 trial of Ziihera, which evaluated zanidatamab as a single agent in previously treated HER2-positive biliary tract cancer, the companies added. The trial attained its primary endpoint of a confirmed objective response rate.</p><p>The partners are currently carrying out the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab with standard-of-care therapy against standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.</p><p>Zymeworks struck a deal with Jazz's Ireland unit in late 2022 to develop and commercialize zanidatamab throughout all indications in the US, Europe, Japan, and all other regions except for those Asia Pacific territories previously licensed by Zymeworks, the companies said.</p><p>Shares of Zymeworks were up 4.5% in recent Thursday premarket activity, while Jazz's stock rose 4.4%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 20:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zymeworks (ZYME) and Jazz Pharmaceuticals (JAZZ) said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485467661","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485467661","pubTimestamp":1732191141,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zymeworks  and Jazz Pharmaceuticals  said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.The regulator's approval was based on the HERIZON-BTC-01 trial of Ziihera, which evaluated zanidatamab as a single agent in previously treated HER2-positive biliary tract cancer, the companies added. The trial attained its primary endpoint of a confirmed objective response rate.The partners are currently carrying out the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab with standard-of-care therapy against standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.Zymeworks struck a deal with Jazz's Ireland unit in late 2022 to develop and commercialize zanidatamab throughout all indications in the US, Europe, Japan, and all other regions except for those Asia Pacific territories prev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","JAZZ":"爵士制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ZYME":"ZYMEWORKS INC (US)"},"translate_title":"Zymeworks、Jazz Pharmaceuticals获得FDA加速批准Ziihera治疗胆道癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1,"ZYME":0.9,"BTCmain":0.66,"XBTmain":0.66},"content_text":"Zymeworks (ZYME) and Jazz Pharmaceuticals (JAZZ) said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.The regulator's approval was based on the HERIZON-BTC-01 trial of Ziihera, which evaluated zanidatamab as a single agent in previously treated HER2-positive biliary tract cancer, the companies added. The trial attained its primary endpoint of a confirmed objective response rate.The partners are currently carrying out the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab with standard-of-care therapy against standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.Zymeworks struck a deal with Jazz's Ireland unit in late 2022 to develop and commercialize zanidatamab throughout all indications in the US, Europe, Japan, and all other regions except for those Asia Pacific territories previously licensed by Zymeworks, the companies said.Shares of Zymeworks were up 4.5% in recent Thursday premarket activity, while Jazz's stock rose 4.4%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485467661"}